top of page

Charbel Moussa


Dr. Moussa is the Director of the GUMC Translational Neurotherapeutics Program and the Laboratory for Dementia and Parkinsonism. He is the Principal Investigator of the Lewy Body Disease Association Research Center of Excellence. His expertise is in geriatric neurology with special focus on movement and memory disorders, and he is a neuroscientist focused on autophagy. Dr. Moussa is a clinical trialist and a translational neuroscience investigator who has designed and completed a number of Phase 1-3 trials in AD, PD, LBD and HD and generated several compounds known as tyrosine kinase inhibitors that can potentially be used as a therapy for neurodegenerative diseases. He discovered the potential use of cancer drugs, including nilotinib and bosutinib as a treatment for neurodegenerative diseases and identified a novel drug target known as discoidin domain receptor (DDR)-1 that can induce autophagic clearance of misfolded proteins in preclinical and clinical settings. Dr. Moussa is an expert on tyrosine kinase inhibitors and their promising effects on neurodegenerative pathologies. Dr. Moussa is published widely in peer reviewed scientific and medical journals on the mechanisms, diagnostics, and treatment of neurodegenerative diseases.

bottom of page